These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9873607)

  • 21. Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.
    Huang W; Naughton MA; Yang H; Su T; Dam S; Wong PW; Arfsten A; Edwards S; Sinha U; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2003 Feb; 13(4):723-8. PubMed ID: 12639567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.
    Guilford WJ; Shaw KJ; Dallas JL; Koovakkat S; Lee W; Liang A; Light DR; McCarrick MA; Whitlow M; Ye B; Morrissey MM
    J Med Chem; 1999 Dec; 42(26):5415-25. PubMed ID: 10639283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P(1) structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides.
    Jia ZJ; Wu Y; Huang W; Goldman E; Zhang P; Woolfrey J; Wong P; Huang B; Sinha U; Park G; Reed A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1651-5. PubMed ID: 12039583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
    Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel benzo-fused lactam scaffolds as factor Xa inhibitors.
    Tamura SY; Goldman EA; Bergum PW; Semple JE
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2573-8. PubMed ID: 10498211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors.
    Jia ZJ; Scarborough RM; Zhang P; Halfon S; Arfsten AE; Sinha U; Zhu BY
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):1004-7. PubMed ID: 19721266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
    Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of benzamidine-type inhibitors of factor Xa.
    Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
    J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors.
    Glunz PW; Douty BD; Decicco CP
    Bioorg Med Chem Lett; 2003 Mar; 13(5):785-8. PubMed ID: 12617891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
    Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
    J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines.
    Ng HP; Buckman BO; Eagen KA; Guilford WJ; Kochanny MJ; Mohan R; Shaw KJ; Wu SC; Lentz D; Liang A; Trinh L; Ho E; Smith D; Subramanyam B; Vergona R; Walters J; White KA; Sullivan ME; Morrissey MM; Phillips GB
    Bioorg Med Chem; 2002 Mar; 10(3):657-66. PubMed ID: 11814853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
    Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
    J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
    Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.
    Koshio H; Hirayama F; Ishihara T; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 May; 12(9):2179-91. PubMed ID: 15080918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors.
    Sheehan SM; Masters JJ; Wiley MR; Young SC; Liebeschuetz JW; Jones SD; Murray CW; Franciskovich JB; Engel DB; Weber WW; Marimuthu J; Kyle JA; Smallwood JK; Farmen MW; Smith GF
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2255-9. PubMed ID: 12824013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploratory solid-phase synthesis of factor Xa inhibitors: discovery and application of p3-heterocyclic amides as novel types of non-basic arginine surrogates.
    Ho JZ; Levy OE; Gibson TS; Nguyen K; Semple JE
    Bioorg Med Chem Lett; 1999 Dec; 9(24):3459-64. PubMed ID: 10617091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.